Organisation paid for research Program year 2023 Source: CMS Open Payments

Atlantic Research Center, LLC

Neither a doctor nor a teaching hospital

Research payments

$244,803

19 payments

Through program year 2023, Atlantic Research Center, LLC is reported as receiving $244,803 in research payments, across 19 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $30,341 1
2022 Research $83,645 4
2021 Research $25,728 5
2020 Research $73,873 5
2019 Research $31,216 4

Breakdown

Who paid Research payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $227,413 10 payments
  2. Amgen Inc. $8,490 4 payments
  3. OptiNose US, Inc. $6,007 2 payments
  4. Teva Pharmaceuticals USA, Inc. $2,782 2 payments
  5. AstraZeneca UK Limited $111 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) $131,224 6 payments
  2. A Cross-Sectional and Longitudinal Observational Primary Data Collection Study to Assess the Validity of the US Asthma Impairment and Risk Questionnaire (AIRQ) as a Tool that Identifies Patients with Asthma at Risk for Adverse Outcomes from Uncontrolled Asthma $65,500 1 payment
  3. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $30,800 4 payments
  4. Ph2b_chronic urticaria $8,490 4 payments
  5. A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. $6,007 2 payments
  6. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma $2,782 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record